Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation.

ABSTRACT:

Background

In the STOP2 (Standardized Treatment of Pulmonary Exacerbations-2) study, intravenous (IV) antimicrobial treatment duration for adults with cystic fibrosis (CF) experiencing pulmonary exacerbations (PEx) was determined based on initial treatment response. The impact of home vs hospital care remains an important clinical question in CF. Our hypothesis was that STOP2 participants treated at home would have less improvement in lung function compared to those treated in the hospital.

Methods

Treating clinicians determined PEx treatment location, which was a stratification factor for STOP2 randomization. Lung function, weight, and symptom recovery were evaluated by treatment location. Propensity scores and inverse probability treatment weighting were used to test for d

SUBMITTER: Sanders DB 

PROVIDER: S-EPMC9148375 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature